PD05-12 PERSISTENT TESTOSTERONE SUPPRESSION AFTER CESSATION OF ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER: AN ELECTRONIC HEALTH RECORDS NETWORK STUDY OF 66 MILLION PEOPLE

Joshua Bitran; Daniel R. Gonzalez; Jesse Ory; Maxwell Towe; Ranjith Ramasamy

doi:10.1097/ju.0000000000001969.12

Back

PD05-12 PERSISTENT TESTOSTERONE SUPPRESSION AFTER CESSATION OF ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER: AN ELECTRONIC HEALTH RECORDS NETWORK STUDY OF 66 MILLION PEOPLE

Journal article

Peer reviewed

PD05-12 PERSISTENT TESTOSTERONE SUPPRESSION AFTER CESSATION OF ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER: AN ELECTRONIC HEALTH RECORDS NETWORK STUDY OF 66 MILLION PEOPLE

Joshua Bitran, Daniel R. Gonzalez, Jesse Ory, Maxwell Towe and Ranjith Ramasamy

Journal of Urology, Vol.206

2021

DOI: https://doi.org/10.1097/ju.0000000000001969.12

Abstract

INTRODUCTION AND OBJECTIVE:Temporary use of Androgen Deprivation Therapy (ADT) is a cornerstone in the treatment of localized prostate cancer. While ADT is typically used for a defined period of ti...

Files and links (2)

url

https://lens.org/000-127-411-448-845View

url

https://www.auajournals.org/doi/10.1097/JU.0000000000001969.12View

Metrics

3 Record Views

Details

Title: PD05-12 PERSISTENT TESTOSTERONE SUPPRESSION AFTER CESSATION OF ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER: AN ELECTRONIC HEALTH RECORDS NETWORK STUDY OF 66 MILLION PEOPLE
Creators: Joshua Bitran
Daniel R. Gonzalez
Jesse Ory
Maxwell Towe
Ranjith Ramasamy
Publication Details: Journal of Urology, Vol.206
Publisher: Ovid Technologies (Wolters Kluwer Health); Netherlands
Academic Unit: UMMG Department of Urology; Miller School of Medicine
Resource Type: Journal article
Record Identifier: 991031722410802976